These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
411 related items for PubMed ID: 11950005
1. Open label study to assess infliximab safety and timing of onset of clinical benefit among patients with rheumatoid arthritis. Shergy WJ, Isern RA, Cooley DA, Harshbarger JL, Huffstutter JE, Hughes GM, Spencer-Smith EA, Goldman AL, Roth SH, Toder JS, Warner D, Quinn A, Keenan GF, Schaible TF, PROMPT Study Group. Profiling Remicade Onset with MTX in a Prospective Trial. J Rheumatol; 2002 Apr; 29(4):667-77. PubMed ID: 11950005 [Abstract] [Full Text] [Related]
2. Chimeric anti-tumor necrosis factor-alpha monoclonal antibody treatment of patients with rheumatoid arthritis receiving methotrexate therapy. Kavanaugh A, St Clair EW, McCune WJ, Braakman T, Lipsky P. J Rheumatol; 2000 Apr; 27(4):841-50. PubMed ID: 10782805 [Abstract] [Full Text] [Related]
3. Sustained benefits of infliximab therapy for dermatologic and articular manifestations of psoriatic arthritis: results from the infliximab multinational psoriatic arthritis controlled trial (IMPACT). Antoni CE, Kavanaugh A, Kirkham B, Tutuncu Z, Burmester GR, Schneider U, Furst DE, Molitor J, Keystone E, Gladman D, Manger B, Wassenberg S, Weier R, Wallace DJ, Weisman MH, Kalden JR, Smolen J. Arthritis Rheum; 2005 Apr; 52(4):1227-36. PubMed ID: 15818699 [Abstract] [Full Text] [Related]
4. A multicenter, double-blind, randomized, placebo controlled trial of infliximab combined with low dose methotrexate in Japanese patients with rheumatoid arthritis. Abe T, Takeuchi T, Miyasaka N, Hashimoto H, Kondo H, Ichikawa Y, Nagaya I. J Rheumatol; 2006 Jan; 33(1):37-44. PubMed ID: 16395748 [Abstract] [Full Text] [Related]
5. Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis. Maini RN, Breedveld FC, Kalden JR, Smolen JS, Davis D, Macfarlane JD, Antoni C, Leeb B, Elliott MJ, Woody JN, Schaible TF, Feldmann M. Arthritis Rheum; 1998 Sep; 41(9):1552-63. PubMed ID: 9751087 [Abstract] [Full Text] [Related]
6. Methotrexate dosage reduction in patients with rheumatoid arthritis beginning therapy with infliximab: the Infliximab Rheumatoid Arthritis Methotrexate Tapering (iRAMT) trial. Fleischmann RM, Cohen SB, Moreland LW, Schiff M, Mease PJ, Smith DB, Keenan G, Kremer JM, iRAMT Study Group. Curr Med Res Opin; 2005 Aug; 21(8):1181-90. PubMed ID: 16083527 [Abstract] [Full Text] [Related]
7. Efficacy of repeated intravenous infusions of an anti-tumor necrosis factor alpha monoclonal antibody, infliximab, in persistently active, refractory juvenile idiopathic arthritis: results of an open-label prospective study. Gerloni V, Pontikaki I, Gattinara M, Desiati F, Lupi E, Lurati A, Salmaso A, Fantini F. Arthritis Rheum; 2005 Feb; 52(2):548-53. PubMed ID: 15693004 [Abstract] [Full Text] [Related]
8. Very early treatment with infliximab in addition to methotrexate in early, poor-prognosis rheumatoid arthritis reduces magnetic resonance imaging evidence of synovitis and damage, with sustained benefit after infliximab withdrawal: results from a twelve-month randomized, double-blind, placebo-controlled trial. Quinn MA, Conaghan PG, O'Connor PJ, Karim Z, Greenstein A, Brown A, Brown C, Fraser A, Jarret S, Emery P. Arthritis Rheum; 2005 Jan; 52(1):27-35. PubMed ID: 15641102 [Abstract] [Full Text] [Related]
9. Treatment of early rheumatoid arthritis: a randomized magnetic resonance imaging study comparing the effects of methotrexate alone, methotrexate in combination with infliximab, and methotrexate in combination with intravenous pulse methylprednisolone. Durez P, Malghem J, Nzeusseu Toukap A, Depresseux G, Lauwerys BR, Westhovens R, Luyten FP, Corluy L, Houssiau FA, Verschueren P. Arthritis Rheum; 2007 Dec; 56(12):3919-27. PubMed ID: 18050189 [Abstract] [Full Text] [Related]
10. Treatment with infliximab plus methotrexate improves anemia in patients with rheumatoid arthritis independent of improvement in other clinical outcome measures-a pooled analysis from three large, multicenter, double-blind, randomized clinical trials. Doyle MK, Rahman MU, Han C, Han J, Giles J, Bingham CO, Bathon J. Semin Arthritis Rheum; 2009 Oct; 39(2):123-31. PubMed ID: 18823645 [Abstract] [Full Text] [Related]
11. Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks. Cohen SB, Emery P, Greenwald MW, Dougados M, Furie RA, Genovese MC, Keystone EC, Loveless JE, Burmester GR, Cravets MW, Hessey EW, Shaw T, Totoritis MC, REFLEX Trial Group. Arthritis Rheum; 2006 Sep; 54(9):2793-806. PubMed ID: 16947627 [Abstract] [Full Text] [Related]
12. Effect of rituximab on physical function and quality of life in patients with rheumatoid arthritis previously untreated with methotrexate. Rigby W, Ferraccioli G, Greenwald M, Zazueta-Montiel B, Fleischmann R, Wassenberg S, Ogale S, Armstrong G, Jahreis A, Burke L, Mela C, Chen A. Arthritis Care Res (Hoboken); 2011 May; 63(5):711-20. PubMed ID: 21557525 [Abstract] [Full Text] [Related]
13. Dose escalation of parenteral methotrexate in active rheumatoid arthritis that has been unresponsive to conventional doses of methotrexate: a randomized, controlled trial. Lambert CM, Sandhu S, Lochhead A, Hurst NP, McRorie E, Dhillon V. Arthritis Rheum; 2004 Feb; 50(2):364-71. PubMed ID: 14872477 [Abstract] [Full Text] [Related]
14. Titration of infliximab treatment in rheumatoid arthritis patients based on response patterns. Flendrie M, Creemers MC, van Riel PL. Rheumatology (Oxford); 2007 Jan; 46(1):146-9. PubMed ID: 16782732 [Abstract] [Full Text] [Related]
15. IgG and IgM anticardiolipin antibodies following treatment with infliximab plus methotrexate in patients with early rheumatoid arthritis. Visvanathan S, Wagner C, Smolen J, St Clair EW, Hegedus R, Baker D, Keenan G. Arthritis Rheum; 2006 Sep; 54(9):2840-4. PubMed ID: 16948115 [Abstract] [Full Text] [Related]
17. Ocrelizumab, a humanized anti-CD20 monoclonal antibody, in the treatment of patients with rheumatoid arthritis: a phase I/II randomized, blinded, placebo-controlled, dose-ranging study. Genovese MC, Kaine JL, Lowenstein MB, Del Giudice J, Baldassare A, Schechtman J, Fudman E, Kohen M, Gujrathi S, Trapp RG, Sweiss NJ, Spaniolo G, Dummer W, ACTION Study Group. Arthritis Rheum; 2008 Sep; 58(9):2652-61. PubMed ID: 18759293 [Abstract] [Full Text] [Related]
18. Changes in biomarkers of inflammation and bone turnover and associations with clinical efficacy following infliximab plus methotrexate therapy in patients with early rheumatoid arthritis. Visvanathan S, Marini JC, Smolen JS, Clair EW, Pritchard C, Shergy W, Pendley C, Baker D, Bala M, Gathany T, Han J, Wagner C. J Rheumatol; 2007 Jul; 34(7):1465-74. PubMed ID: 17552048 [Abstract] [Full Text] [Related]
19. The effect of infliximab and timing of vaccination on the humoral response to influenza vaccination in patients with rheumatoid arthritis and ankylosing spondylitis. Elkayam O, Bashkin A, Mandelboim M, Litinsky I, Comaheshter D, Levartovsky D, Mendelson E, Wigler I, Caspi D, Paran D. Semin Arthritis Rheum; 2010 Jun; 39(6):442-7. PubMed ID: 19246078 [Abstract] [Full Text] [Related]
20. Clinical outcomes of patients with rheumatoid arthritis after switching from infliximab to etanercept. Haraoui B, Keystone EC, Thorne JC, Pope JE, Chen I, Asare CG, Leff JA. J Rheumatol; 2004 Dec; 31(12):2356-9. PubMed ID: 15570634 [Abstract] [Full Text] [Related] Page: [Next] [New Search]